<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03203148</url>
  </required_header>
  <id_info>
    <org_study_id>2017-HeartCentre-003</org_study_id>
    <nct_id>NCT03203148</nct_id>
  </id_info>
  <brief_title>Two Monitors for Measuring the Activated Clotting Time: A Comparison</brief_title>
  <official_title>Comparison of Two Point of Care Techniques Mechanical Versus Biochemical Activated Clotting Time</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Umeå University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Umeå University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this observational study a comparison is made between two different monitors for
      measurement of the activated clotting time (ACT): mechanical versus biochemical techniques
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The ACT is a functional test influenced by multiple factors, such as platelet function,
      coagulation factors, temperature and contact activation inhibitors. Results produced by
      different monitors are also prone to vary influenced by the specific method employed to
      perform the test.

      The present clinical study aims to compare two types of ACT monitors: the Hemostatic
      Management System Plus (Medtronic) and i-STAT (Abbott) in 20 cardiac surgical patients by
      performing five intraoperative consecutive measurements using anti factor Xa as a reference
      for the actual heparin concentration.

      Inclusion criteria comprised patients aged 20-80 years, scheduled for coronary bypass
      surgery.

      Measurements: 1) before induction of anaesthesia 2 ) after heparin bolus 3) rewarming of the
      patient 4) weaning from cardiopulmonary bypass 5) after protamine administration.

      The Hemostatic System Plus ACT monitor served as reference for dosing of heparin in all
      patients. The study protocol did not intervene with the standard protocol used for
      anticoagulation. No patient interventions were made.

      It is hypothesised that the i-STAT ACT monitor has a better correlation with the actual
      heparin concentration than the Hemostatic Management System Plus
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 18, 2017</start_date>
  <completion_date type="Anticipated">November 1, 2017</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Activated Clotting time</measure>
    <time_frame>Intraoperative</time_frame>
    <description>Coagulation Measure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-Factor Xa</measure>
    <time_frame>Intraoperative</time_frame>
    <description>Reference for heparin plasma concentration</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Cardiopulmonary Bypass</condition>
  <condition>Blood Coagulation</condition>
  <condition>Point-of-Care Testing</condition>
  <arm_group>
    <arm_group_label>CABG Surgical Patients</arm_group_label>
    <description>Patients undergoing coronary bypass grafting with cardiopulmonary bypass</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Point-of-Care ACT</intervention_name>
    <description>Comparison between two point-of-care devices for measurement of the activated clotting time</description>
    <arm_group_label>CABG Surgical Patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients admitted for routine coronary bypass surgery with the use of cardiopulmonary
        bypass
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria: Patients listed for coronary bypass surgery, -

        Exclusion Criteria: Primary coagulation disorder, diabetes mellitus, ongoing
        anti-coagulation therapy, emergency, reduced kidney function, allergy for fish, sea food
        and protamine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Magnus Hedström, MD</last_name>
    <role>Study Director</role>
    <affiliation>Heart Centre, Umeå University Hospital, Sweden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Micael Appelblad, PhD</last_name>
    <phone>+46 90 7853650</phone>
    <email>micael.appelblad@kumu.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Samuel Nilsson, MS</last_name>
    <phone>+46907853650</phone>
    <email>samuel.nilsson@vll.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Heart Centre Umeå University Hospital</name>
      <address>
        <city>Umeå</city>
        <zip>S-901 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Micael Appelblad, PhD</last_name>
      <phone>+46907853650</phone>
      <email>micael.appelblad@umu.se</email>
    </contact>
    <contact_backup>
      <last_name>Samuel Nilsson, MS</last_name>
      <phone>+46907853650</phone>
      <email>samuel.nilsson@vll.se</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <reference>
    <citation>Teufelsbauer H, Proidl S, Havel M, Vukovich T. Early activation of hemostasis during cardiopulmonary bypass: evidence for thrombin mediated hyperfibrinolysis. Thromb Haemost. 1992 Sep 7;68(3):250-2.</citation>
    <PMID>1440486</PMID>
  </reference>
  <reference>
    <citation>Hattersley PG. Progress report: the activated coagulation time of whole blood (ACT). Am J Clin Pathol. 1976 Nov;66(5):899-904.</citation>
    <PMID>983997</PMID>
  </reference>
  <reference>
    <citation>Guzzetta NA, Monitz HG, Fernandez JD, Fazlollah TM, Knezevic A, Miller BE. Correlations between activated clotting time values and heparin concentration measurements in young infants undergoing cardiopulmonary bypass. Anesth Analg. 2010 Jul;111(1):173-9. doi: 10.1213/ANE.0b013e3181e13470. Epub 2010 Jun 2.</citation>
    <PMID>20519414</PMID>
  </reference>
  <reference>
    <citation>Svenmarker S, Appelblad M, Jansson E, Häggmark S. Measurement of the activated clotting time during cardiopulmonary bypass: differences between Hemotec ACT and Hemochron Jr apparatus. Perfusion. 2004;19(5):289-94.</citation>
    <PMID>15506033</PMID>
  </reference>
  <reference>
    <citation>Raymond PD, Ray MJ, Callen SN, Marsh NA. Heparin monitoring during cardiac surgery. Part 1: Validation of whole-blood heparin concentration and activated clotting time. Perfusion. 2003 Sep;18(5):269-76.</citation>
    <PMID>14604242</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2017</study_first_submitted>
  <study_first_submitted_qc>June 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2017</study_first_posted>
  <last_update_submitted>June 28, 2017</last_update_submitted>
  <last_update_submitted_qc>June 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardiopulmonary Bypass</keyword>
  <keyword>Blood Coagulation Testing</keyword>
  <keyword>Point-of-Care Testing</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

